Quality by Design in Formulation Development
Quality by Design, commonly abbreviated QbD, is a systematic, science- and risk-based approach to pharmaceutical development, formalised internationally...
Quality by Design, commonly abbreviated QbD, is a systematic, science- and risk-based approach to pharmaceutical development, formalised internationally through ICH Q8(R2), which holds that quality should be designed into a product from its inception rather than tested into it after manufacture. The QbD process begins with definition of the Quality Target Product Profile, or QTPP, a prospective summary of the quality characteristics that the finished dosage form must possess to be safe and effective for its intended use — for example, a film-coated tablet intended for oral administration with a specified dissolution performance, content uniformity, and shelf-life.
From the QTPP, the formulation scientist identifies the Critical Quality Attributes, the physical, chemical, biological, or microbiological properties that must be controlled within an appropriate range to ensure the desired product quality is achieved — commonly including assay, dissolution, content uniformity, and impurity levels. Risk assessment tools are then applied to identify which formulation and process variables, termed Critical Process Parameters and Critical Material Attributes, exert the greatest influence on these Critical Quality Attributes, focusing subsequent experimental effort where it will yield the greatest benefit.
Design of Experiments, or DoE, provides the statistical methodology through which the relationship between these critical variables and the resulting quality attributes is systematically mapped, typically using response surface methodology to identify an optimal formulation and to define a design space — a multidimensional combination of input variables and process parameters that has been demonstrated to provide assurance of quality. Operating within an approved design space affords manufacturers meaningful regulatory flexibility, since movements within the space do not constitute a formal post-approval change requiring additional regulatory review.
The QbD paradigm represents a fundamental philosophical shift from the traditional quality-by-testing model, in which a fixed process was validated and quality was subsequently confirmed by end-product testing, toward a model in which deep mechanistic understanding of the formulation and process is used to build quality assurance directly into the design itself. This shift has profound implications not only for formulation robustness but also for manufacturing flexibility, continuous improvement, and the efficiency of regulatory interactions, and its principles recur throughout the remainder of this chapter as each dosage form category is addressed in turn.